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without the risk of alkalosis. The data also suggest that theEffects of bicarbonate- and lactate-buffered replacement fluids
use of RF-bic during CVVH reduces cardiovascular events inon cardiovascular outcome in CVVH patients.
critically ill patients with acute renal failure, particularly thoseBackground. Bicarbonate-buffered replacement fluid (RF-bic)
with previous cardiovascular disease or heart failure.in continuous venovenous hemofiltration (CVVH) may be supe-
rior to lactate-buffered replacement fluid (RF-lac) in acute renal
failure. In an open, randomized, multicenter study, we investi-
gated the effects of RF-bic and RF-lac on cardiovascular out- Despite extensive clinical experience with dialysis income in patients requiring CVVH following acute renal failure.
acute renal failure and many technical advances in theMethods. One hundred seventeen patients between the age
delivery of extracorporeal care over the past decades,of 18 and 80 years were randomized to CVVH either with
RF-bic (N 5 61) or RF-lac (N 5 56). Patients were treated the mortality rate of critically ill patients with acute renal
with CVVH for five days or until either renal function was failure requiring dialysis therapy remains high [1–3]. The
restored or the patient was removed from the study. Data were persistent high mortality has been attributed to a reduc-
analyzed on day 5 or according to the “last observation carried
tion of cases with uncomplicated isolated acute renalforward” (LOCF) option. Adverse events were classified ac-
failure and an increase of patients with multiple organcording to the WHO-Adverse Reaction Terminology system.
Results. Blood lactate levels were significantly lower and dysfunction syndrome, including acute renal failure [4].
blood bicarbonate levels were significantly higher in patients One goal of continuous renal replacement therapy is to
treated with RF-bic than in those treated with RF-lac (lactate, maintain normal or near normal acid-base balance in
17.4 6 8.5 vs. 28.7 6 10.4 mg/dL, P , 0.05; bicarbonate, 23.7 6 patients with acute renal failure, thereby preventing det-0.4 vs. 21.8 6 0.5 mmol/L, P , 0.01). The number of hypoten-
rimental effects of acidemia on cardiovascular perfor-sive crises was lower in RF-bic–treated patients than in RF-lac–
mance, hepatic metabolism, and hormonal response [5].treated patients (RF-bic 14 out of 61 patients, RF-lac in 29 out
of 56 patients; 0.26 6 0.09 vs. 0.60 6 0.31 episodes per 24 h, In conventional hemofiltration solutions, lactate, which
P , 0.05). Nine out of 61 patients (15%) treated with RF-bic is converted to bicarbonate on an equimolar basis under
and 21 out of 56 patients (38%) treated with RF-lac developed physiological conditions, is used as the buffer to correctcardiovascular events during CVVH therapy (P , 0.01). A
acidosis [5]. However, there are several studies sug-multiple regression analysis showed that the occurrence of
gesting that lactate can exert negative effects on meta-cardiovascular events was dependent on replacement fluid and
previous cardiovascular disease and not on age or blood pres- bolic and on hemodynamic parameters [5–7]. In critically
sure. Patients with cardiac failure died less frequently in the ill patients with multiple organ dysfunction, conversion
group treated with RF-bic (7 out of 24, 29%) than in the group of lactate to bicarbonate is often diminished, and lac-
treated with RF-lac (12 out of 21, 57%, P 5 0.058). In patients
tatemia caused by lactate infusion may have negativewith septic shock, lethality was comparable in both groups
effects. The possibility of bicarbonate-buffered replace-(RF-bic, 10 out of 27, 37%; RF-lac, 7 out of 20, 35%, P 5 NS).
Conclusions. The results show that the administration of ment fluids (RF-bics) has been pointed out as an alterna-
RF-bic solution was superior in normalizing acidosis of patients tive that may improve the prognosis of critically ill pa-
tients with acute renal failure [8–10]. However, to date
there are no randomized studies comparing the effects ofKey words: acute renal failure, dialysate, renal replacement fluid, he-
RF-bics and lactate-buffered replacement fluids (RF-lacs)mofiltration, blood lactate, glucose, heart failure, cardiovascular dis-
ease. on prognosis. The objective of the present study was to test
the hypothesis of whether the use of RF-bic in continuousReceived for publication October 14, 1999
venovenous hemofiltration (CVVH) is superior in pre-and in revised form May 2, 2000
Accepted for publication May 10, 2000 venting cardiovascular complications to RF-lac. In an
open, multicenter, randomized study, we investigated theÓ 2000 by the International Society of Nephrology
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Table 1. Composition of the replacement fluids after the patient had been carefully examined. Vascular
access was obtained by femoral or jugular vein catheter-RF-bic RF-lac
ization. Patients received machine hemofiltration usingFree of K1 With K1 Free of K1 With K1
commercially available hollow-fiber hemofilters with aNa1 140 140 135 135
blood flow rate limited to a maximum of 200 mL/min.K1 0 2 0 2
Ca21 1.5 1.5 1.88 1.875 Anticoagulation was achieved with heparin, given in
Mg21 0.5 0.5 0.75 0.75 doses to maintain an activated partial thromboplastinCl2 109 111 106.5 108.5
time between 100 and 150 seconds. The replacement fluidsHCO23 35 35 — —
Lactate — — 33.75 33.75 containing 2 mmol/L K1 or potassium-free solutions were
Glucose 5.6 5.6 7.5 8.3 chosen by the attending physicians on the basis of the
Values are mmol/L. patient’s serum potassium values. Temperature of the
replacement fluids was adjusted at 36.58C. Rates of ultra-
filtration and fluid replacement were approximately 1000
mL/hour. Arterial blood pressure was monitored through-effects of RF-bic and RF-lac on cardiovascular outcome
out treatment using a radial or femoral arterial catheter.in patients requiring CVVH following acute renal failure.
Vasopressor therapy was chosen by the attending physi-
cians in order to treat heart failure and to elevate theMETHODS
blood pressure in hypotensive states. Patients were
We conducted an open, randomized, multicenter study. treated with continuous hemofiltration for five days or
The investigation was approved by the ethics committee until either renal function was restored or the patient
of the University of Muenster. The patients or the pa- was withdrawn from the study because of adverse events
tients’ next of kin gave written informed consent to par- or medical judgment of the investigators. In either of
ticipate in this trial. Patients who developed acute renal these cases, a final assessment of the patient’s status was
failure and who were treated at an medical intensive care performed before the patient was removed from the
unit were considered for enrollment into the study. During study. Data were analyzed on day 5 or according to
a screening period, which took place within 24 hours the “last observation carried forward” (LOCF) option.
prior to the start of continuous hemofiltration, patients Adverse events were classified according to the WHO-
were to be evaluated for eligibility. During this period, ART system [11].
the inclusion and exclusion criteria, medical history, com- Clinical data and laboratory parameters were evalu-
plete medical examination, and laboratory parameters ated according to the study protocol. The fluid volume
were evaluated. The clinical status was assessed by the
status was assessed by the attending physician based on
APACHE II classification system. To be eligible for par-
clinical examination, x-ray of the chest and hemody-ticipating in the study, male or female patients had to
namic parameters determined by central venous pres-be between 18 and 80 years of age. Inclusion criteria
sure, and, in some patients, right heart catheterization.were the development of acute oliguric or anuric renal
The following data were documented once daily atfailure, acute azotemia, or acute deterioration of renal
6 p.m.: clinical status, clinical complications, diuresis perfunction associated with volume overload refractory to
24 hours, frequency of hypotensive episodes (defined asdiuretic therapy. Patients who met the following criteria
systolic blood pressure drop below 70 mm Hg), dailywere excluded from study participation: chronic renal
fluid balance, infusion site, and anticoagulation. Bloodfailure (serum creatinine level .3 mg), serum lactate
count, serum creatinine, serum urea, alanine aminotrans-levels .45 mg/dL (.5 mmol/L), blood pH ,7.30, malig-
ferase (ALT), aspartate aminotransferase (AST), g-glu-nant disease, pregnancy, or lactation. One hundred sev-
tamyltransferase (g-GT), total protein, and fibrinogenenteen patients were included into the study. The ran-
levels were also determined once daily. Respiratory rate,domization lists were generated by the computer program
central venous pressure, electrolytes, glucose, lactate,RANCODE version 3.1 (Gauting, Munich, Germany).
and activated clotting time (ACT) were evaluated twiceSixty-one patients were randomized to CVVH using a
daily, at 6 p.m. and at 6 a.m. Blood flow, ultrafiltration,RF-bic, 56 patients to CVVH using RF-lac. Since the
substitution volume, body temperature, heart rate, sys-RF-bic had to be prepared by mixing a base solution
tolic and diastolic blood pressure, and blood gas analysis(4000 mL) and an electrolyte solution (500 mL) immedi-
were documented four times daily (6 p.m., 12 p.m., 6ately before administration, a blinding procedure was
a.m., and 12 a.m.). The study was regularly controlledtechnically not possible. The replacement fluids were
by monitors. The monitor checked the data entered inmanufactured by Fresenius Medical Care (Bad Hom-
the clinical report forms in order to verify adherence toburg, Germany). The final composition of the replace-
the study protocol. Data obtained in the study werement fluids is shown in Table 1.
Continuous venovenous hemofiltration was performed entered into a computer database (Access 2.0).
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Table 2. Baseline clinical characteristics
Variable RF-bic RF-lac P
N 61 56
Age years 59615 64610 NS
Weight kg 79614 80615 NS
Height cm 17269 7168 NS
Gender female/male 15/46 16/40 NS
APACHE II score 2661.0 2760.9 NS
Blood pressure mm Hg 11763/5962 11464/5862 NS
Heart rate/min 10663 10763 NS
Temperature 8C 37.760.18 38.060.16 NS
Central venous pressure cm H2O 1361 1161 NS
Number of patients on pressure support 56 (92%) 48 (87%) NS
Number of patients on ventilator support 55 (90%) 49 (89%) NS
Number of patients with multiorgan failure 6 (10%) 4 (7%) NS
Number of patients with relevant previous disease
Respiratory tract 25 (41%) 21 (38%) NS
Cardiovascular system 41 (67%) 43 (77%) NS
Coronary artery disease 26 (43%) 24 (43%) NS
Other cardiac disease 8 (13%) 10 (18%) NS
Previous operation 47 (77%) 43 (77%) NS
Medication previous to acute renal failure 50 (82%) 46 (82%) NS
Causes of acute renal failure
Cardiovascular disease 26 (43%) 27 (48%) NS
Thereof acute heart failure 24 (39%) 21 (38%) NS
Sepsis 30 (49%) 23 (41%) NS
Metabolic 5 (8%) 6 (11%) NS
Data are mean 6 SEM. Abbreviations are: RF-bic, bicarbonate-buffered replacement fluid; RF-lac, lactate-buffered replacement fluid; NS, not significant.
Table 3. Baseline laboratory parametersStatistics
Variable RF-bic RF-lac PStatistical analysis was performed by a statistical insti-
N 61 56tute (Harrison Clinical Research, Munich, Germany).
Blood pH 7.3760.01 7.3960.01 NSData were expressed as mean 6 SEM. Statistical com-
Blood bicarbonate mmol/L 2360.8 2360.8 NS
parisons between the groups were carried out using the Blood base excess (BE) 20.9860.71 21.0360.91 NS
pCO2 mm Hg 4262 3962 NSt-test for continuous variables and the chi-square test
pO2 mm Hg 10668 9364 NSfor qualitative variables. A multiple logistic regression
Blood lactate mg/dL 24.562.9 26.462.5 NS
analysis was used to assess the independent relationship Hemoglobin g/dL 10.860.3 10.960.3 NS
Serum creatinine mg/dL 3.360.2 3.860.3 NSbetween treatment and cardiovascular outcome. Values
Serum urea-N mg/dL 132612 146614 NSof P , 0.05 were considered to be statistically significant.
ALT U/L 213691 142662 NS
AST U/L 2556148 169666 NS
g-GT U/L 75615 5868 NS
RESULTS Total protein g/L 51.761.3 51.461.1 NS
Fibrinogen mg/dL 495624 561627 NSBaseline characteristics of the groups treated with
Glucose mg/dL 187610 186611 NS
RF-bic and with RF-lac in venovenous hemofiltration
Data are mean 6 SEM.therapy are shown in Table 2. Age tended to be higher
in the group treated with RF-lac than in the group treated
with RF-bic, but the difference was not statistically sig-
nificant. There were no differences in gender, weight, (Table 2). Laboratory parameters at baseline are shown
in Table 3. There were no significant differences of labo-height, and APACHE II score at baseline. Blood pres-
sure, heart rate, temperature, and central venous pres- ratory values at baseline between the group treated with
RF-bic and RF-lac (Table 2).sure were also similar in both groups at baseline. The
proportion of patients with ventilator or pressure sup- The hemofiltration regimen was comparable between
both study groups. Hemofiltration was applied for 3.64 6port and multiorgan failure was not different between
both study groups. Relevant previous diseases and medi- 0.2 days in RF-bic–treated patients versus 3.40 6 0.2
days in RF-lac–treated patients (P 5 NS). Mean bloodcations given prior to the onset of acute renal failure
were comparable in both groups (Table 2). Acute renal flow was 137 6 7 mL/min in RF-bic–treated and 132 6
7 mL in RF-lac–treated patients (P 5 NS). The meanfailure was due to cardiovascular disease and sepsis in
most patients. There were no significant differences in 24-hour ultrafiltration rate was 28794 6 2193 mL in
RF-bic–treated and 31472 6 2100 mL in RF-lac–treatedthe causes of acute renal failure between the study groups
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Table 4. Clinical and biochemical parameters at end of the study
Variable RF-bic RF-lac P
N 61 56
APACHE II score 2661.0 2760.9 NS
Blood pressure mm Hg 12463/6262 12964/6062 NS
Heart rate min21 10262 9963 NS
Temperature 8C 37.360.12 37.260.10 NS
CVP cm H2O 9.860.7 10.560.7 NS
Mean respiratory rate min21 20.562.0 23.462.1 NS
Mean PEEP cm H2O 6.360.39 5.960.40 NS
Blood bicarbonate mmol/L 23.760.4 21.860.5 ,0.01
Blood lactate mg/dL 17.468.5 28.7610.4 ,0.05
Intravenous bicarbonate
(1 mmol/mL, mL/24 h) 1367 68639 ,0.01
Mean pH 7.3760.01 7.3960.01 NS
Fig. 1. Frequency of cardiovascular events and mean number of hypo-pCO2 mm Hg 38.360.8 37.461.1 NS tensive episodes per 24 hours before the end of the study in patientspO2 mm Hg 9663 10264 NS with acute renal failure treated with bicarbonate-buffered (j; RF-bic;Mean blood base excess (BE) 20.660.4 22.260.5 ,0.01
N 5 61) and lactate-buffered (h; RF-lac; N 5 56) replacement fluidsHemoglobin g/dL 10.760.3 10.460.3 NS
during continuous venovenous hemofiltration (CVVH).Serum creatinine mg/dL 2.660.3 2.360.2 NS
Serum urea-N mg/dL 10969 107611 NS
ALT U/L 88628 56616 NS
AST U/L 70618 40616 NS
g-GT U/L 112618 89614 NS (P , 0.01; Fig. 1). The number of hypotensive episodes
Total protein g/L 56.761.8 55.961.6 NS
was lower in the group treated with RF-bic than in theFibrinogen mg/dL 509631 490638 NS
Glucose mg/dL 16269 182610 NS group treated with RF-lac. Fourteen hypotensive events
Data are mean 6 SEM. Abbreviations are: CVP, central vein pressure; PEEP, were observed in the RF-bic–treated group, and 29 hypo-
positive endexpiratory pressure; i.v., intravenously; BE, base excess. tensive episodes were observed in the RF-lac–treated
group during the last 24 hours before the end of the study.
On average, the mean number of hypotensive episodes
was significantly lower in RF-bic–treated as comparedpatients (P 5 NS). The mean 24-hour substitution vol-
with RF-lac–treated patients (P , 0.05; Fig. 1). The inci-ume was 26476 6 2044 mL in RF-bic–treated and
dence of hypotension was 0.26 6 0.09 episodes/24 hours28985 6 2727 mL in RF-lac–treated patients (P 5 NS).
in RF-bic–treated patients and 0.60 6 0.31 episodes/24Net ultrafiltration and ultrafiltration/kg body weight was
hours in RF-lac–treated patients.2325 6 191 mL and 29 6 3 mL/kg in RF-bic–treated
Forty-four (38%) patients died during the study pe-patients versus 2490 6 218 mL and 31 6 3 mL/kg in
riod. In the group treated with RF-bic, 20 of 61 (33%)
RF-lac–treated patients (P 5 NS). The mean diuresis
patients died during hemofiltration therapy, and in the
did not differ between both groups. Diuresis was 1254 6 group treated with RF-lac, 24 of 56 (43%) patients died
257 mL/24 hour in the RF-bic–treated and 1587 6 403 (P 5 NS). The mortality rate just failed to be significantly
mL/24 hour in the RF-lac–treated group (P 5 NS). different between both study groups in patients with
Clinical parameters and laboratory data on day 5 or cardiac failure. Seven of 24 (29%) patients with cardiac
according to the LOCF option are shown in Table 4. failure died in the group treated with RF-bic, while 12
Blood pressure levels and heart rate were not significantly of 21 (57%) patients with cardiac failure died in the
different between both study groups. Serum bicarbonate group treated with RF-lac (P 5 0.058). In patients with
levels were significantly lower in the patients treated sepsis, mortality was comparable in both groups. Ten of
with RF-lac than in those treated with RF-bic (P , 0.01). 27 (37%) septic patients died in the group treated with
This held true despite the fact that patients treated with RF-bic, and 7 of 20 (35%) septic patients died in the
RF-lac received significantly more intravenous bicarbon- group treated with RF-lac (P 5 NS).
ate than patients treated with RF-bic replacement fluid The logistic regression analysis showed that the occur-
(Table 4). Blood lactate levels were significantly lower rence of cardiovascular events during hemofiltration
in RF-bic–treated than in the RF-lac–treated patients therapy was dependent on the administered replacement
(P , 0.05). fluid and previous cardiovascular disease, and not on
Cardiovascular complications during hemofiltration age or blood pressure (Table 5). There was a significant
therapy were observed less frequently in the group treated relationship between the development of cardiovascular
with RF-bic as compared with the group treated with events and the type of replacement fluid used during
RF-lac. Nine out of 61 (15%) RF-bic–treated patients hemofiltration (P , 0.01). The effects of the replacement
and 21 out of 56 (38%) RF-lac–treated patients devel- fluid on cardiovascular complications were independent
of previous cardiovascular disease and age. The relation-oped cardiovascular complications during hemofiltration
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Table 5. Logistic regression analysis for the occurrence of of age and previous cardiovascular disease in the logistic
cardiovascular events (dependent variable)
regression analysis. Moreover, our data also suggest that
Correlation RF-bic during hemofiltration may decrease mortality in
Independent variable coefficient t-value p-value patients with cardiac failure, whereas the death rate was
Replacement fluid comparable between bicarbonate- and lactate-treated
(RF-bic/RF-lac) 0.217 8.259 0.0041
septic patients. The data of the present study confirmCardiovascular disease
prior to enrollment 0.209 7.840 0.0051 previous studies showing that the administration of RF-
Age years 0.106 3.397 0.065 bics during hemofiltration is superior in normalizing aci-
Body mass index kg/m2 20.346 2.158 0.141
dosis when compared with RF-lacs [9, 10].APACHE II score 0.033 0.050 0.147
Hemoglobin level Lactate is used in commercially available replacement
at baseline g/L 0.000 0.213 0.821 fluids employed for continuous hemofiltration therapy
Temperature
as the buffer to correct acidosis. Under physiologicalat baseline 8C 0.000 0.146 0.702
Systolic blood pressure conditions, the resulting exogenous lactate load of 40
at baseline mm Hg 0.000 0.491 0.483 to 45 mmol/L during continuous hemofiltration can be
Diastolic blood pressure
converted to bicarbonate on an equimolar basis by theat baseline mm Hg 0.000 0.087 0.767
Heart rate/ min 0.000 0.020 0.882 liver [12]. However, in conditions in which lactate over-
Blood bicarbonate production occurs or the conversion pathways are im-
at baseline mmol/L 20.059 1.099 0.294
paired, such as in hypoxic states or circulatory failure,Blood lactate level
at baseline mg/dL 0.000 0.102 0.749 in preexisting lactic acidemia or in patients with liver
Serum creatinine level failure, complications may arise from the use of lactate-
at baseline mg/dL 20.059 2.473 0.111
based replacement fluids [13, 14]. The use of RF-bicSerum urea
at baseline mg/dL 0.081 2.870 0.092 during CVVH has therefore been recommended in pa-
tients with lactic acidemia and severe liver failure [5, 6].
However, in the present study, patients with lactic acide-
mia were not enrolled, and most patients had normal
liver function at entry into study. Thus, the data of theship between cardiovascular complications and replace-
ment fluid was also independent of the APACHE II present trial suggest that the use of RF-bics should also
be recommended in critically ill patients with normalscore at baseline, temperature, blood pressure, heart
rate, hemoglobin, blood bicarbonate, blood lactate, se- blood lactate levels or liver function.
The exogenous lactate load during continuous hemo-rum creatinine, and serum urea-N concentrations at
baseline. The presence of previous cardiovascular dis- filtration should be taken in the context of the hypermet-
abolic, hypodynamic, or hyperdynamic cardiovascularease was a significant independent predictor for the de-
and systemic inflammatory state of critically ill patients.velopment of cardiovascular events (P , 0.01; Table 5).
This syndrome of critically ill patients is characterizedThere was also a relationship between the development
by excess production of lactate even in the absence ofof cardiovascular complications during hemofiltration
lactatemia, increased oxygen consumption, and elevatedtherapy and age, but the relationship just failed to reach
protein catabolism with increased urea nitrogen produc-statistical significance (P 5 0.065). The cardiovascular
tion [15–17]. There is some evidence that the administra-event rate was not related to baseline APACHE II score,
tion of large amounts of lactate can also result in anblood pressure, heart rate, temperature, blood bicarbon-
increased protein catabolic rate [18]. The adverse effectsate, blood lactate, hemoglobin, serum creatinine, and
of RF-lac on protein catabolism can be attributed to anserum urea-N concentrations (Table 5).
increased lactate:pyruvate ratio [18]. It has been shown
that excessively elevated lactate:pyruvate ratios can pro-
DISCUSSION mote liver glucose production at the expense of amino
The objective of the present randomized study was to acids in isolated hepatocytes, thus increasing protein ca-
investigate whether the use of RF-bic in CVVH would tabolism [19]. Since protein catabolic rates are already
improve cardiovascular outcome in critically ill patients excessively increased in critically ill patients with acute
with acute renal failure when compared with RF-lac. The renal failure, this abnormality may be exacerbated by
results presented here clearly demonstrate that cardiovas- the administration of large lactate loads. The increase
cular events during CVVH occurred less frequently in in the intracellular lactate:pyruvate ratio was also been
patients treated with RF-bics as compared with patients associated with a rise in adenosine diphosphate (ADP)
treated with RF-lacs. The number of hypotensive epi- levels and depletion of cellular energy stores, which can
sodes was also lower in patients treated with RF-bics impair oxygen delivery and left ventricular function [7, 20].
than with RF-lacs. The beneficial effect of RF-bic on the It has been shown that high amounts of administered
lactate result in an increase in intracellular lactate con-development of cardiovascular events was independent
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